Pulmonary Allograft
Pulmonary Allograft - Related Videos
08:17
Murine Echocardiography of Left Atrium, Aorta, and Pulmonary Artery
0 Views •
Cited by 8 •
2017
The following protocol describes the methodology for the acquisition and analysis of echocardiographic images used to obtain the Left Atrial Volume (LAV), Aorta (Ao) diameter, and Pulmonary Artery (PA) diameter in mice. This technique is a non-invasive, non-terminal procedure that allows assessment of the cardiopulmonary function.
09:14
Surgical Approach to Full Soft Tissue Face Allograft Procurement for Vascularized Composite Allotransplantation
0 Views •
2025
This protocol details the surgical technique used to harvest and prepare a full-face allograft for transplantation in patients with severe facial disfigurements, focusing primarily on soft tissue procurement with limited bony harvest restricted to the nasal framework.
05:10
Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice
0 Views •
Cited by 5 •
2010
This protocol describes the isolation and dissociation of mouse medulloblastoma tissue, and subsequent allografting of the tumor cells into immunocompromised recipient mice in order to initiate secondary medulloblastoma.
06:59
Catheter-based Endovascular Angioplasty for Fibrosing Mediastinitis-associated Pulmonary Vein Stenosis
0 Views •
2025
Pulmonary vein stenosis (PVS) is a life-threatening complication of fibrosing mediastinitis (FM), with a poor prognosis if not properly treated. Currently, catheter-based endovascular angioplasty is a promising therapeutic strategy for FM-associated PVS. This protocol primarily outlines a stepwise approach to the transcatheter procedure for FM-associated PVS.
13:16
Computed Tomography and Optical Imaging of Osteogenesis-angiogenesis Coupling to Assess Integration of Cranial Bone Autografts and Allografts
0 Views •
Cited by 7 •
2015
Implantation of autologous and allogeneic bone grafts constitute accepted approaches to treat major craniofacial bone loss. Yet the effect of graft composition on the interplay among neovascularization, cell differentiation and bone formation is unclear. We present a multimodal imaging protocol aimed to elucidate the angiogenesis-osteogenesis interdependence at the graft proximity.
FAQs
The recipient’s immune system detects donor antigens, especially human leukocyte antigens, as foreign. This recognition can activate T cells, which then contribute to injury of the transplanted lung. The resulting immune response is clinically important because it can produce acute rejection soon after transplantation or support chronic rejection that progressively threatens long-term graft function.
Human leukocyte antigens are prominent donor markers considered by the recipient’s immune system when distinguishing self from foreign tissue. Differences between donor and recipient can intensify immune recognition and T-cell activation. For that reason, tissue matching forms part of the strategy for reducing rejection risk, although matching does not eliminate the need for immunosuppressive treatment and surveillance.
Acute rejection and chronic rejection represent different time-related patterns of graft injury. Acute rejection reflects an early immune response after transplantation, whereas chronic rejection develops over the longer term and can progressively impair graft preservation. Distinguishing these patterns helps clinicians interpret changes in graft function and plan continued monitoring and treatment decisions.
Long-term function depends on controlling immune recognition while preserving enough immune defense to limit complications. Tissue matching can reduce immunologic mismatch, and immunosuppressive therapy restrains T-cell-mediated injury. Close monitoring provides ongoing assessment of graft function and possible rejection. Together, these measures address the competing risks of graft damage, infection, and other treatment-related complications.
Post-transplant care centers on maintaining graft function and detecting complications early. Clinicians use immunosuppressive therapy to limit rejection, consider tissue matching as part of donor-recipient assessment, and perform close monitoring after transplantation. This continuing management is necessary because the same treatment that suppresses damaging immune responses can also increase susceptibility to infection and other complications.
Pulmonary allografts are used in lung transplantation when a patient’s lungs have sustained irreversible damage and replacement is required. Their clinical value extends beyond the operation itself: outcomes depend on preserving function over time while managing rejection and treatment complications. Thus, they are relevant to advanced respiratory disease, transplant medicine, and long-term post-transplant care.
Research involving pulmonary allografts helps investigators examine immune tolerance, graft injury, and long-term transplant outcomes in a clinically important setting. Studying how donor antigens activate recipient T cells, how rejection develops, and how immunosuppression affects graft preservation can connect basic immune mechanisms with the monitoring and management of lung transplant recipients.
Close monitoring is essential because clinicians must follow graft function while watching for immune-mediated injury and complications of immunosuppressive therapy. Surveillance supports recognition of acute or chronic rejection and helps assess whether the transplanted lung remains functional. It also provides an opportunity to balance rejection prevention against infection and other consequences of suppressing the recipient’s immune system.